Mumbai: Dr Reddy's Laboratories Ltd (DRL) has set up a finished dosages plant at Visakhapatnam, its seventh facility.
The state-of-the-art plant is designed to manufacture a broad range of products, including cytotoxic and anti-hormonal products and injectibles, catering to the international market for the treatment of cancer, hormonal imbalances and other diseases.
The facility is also designed to cater to the manufacturing needs of international pharmaceutical companies.
DRL had, in March, inaugurated a manufacturing facility at Baddi, Himachal Pradesh.
"Our organisation's multi-disciplinary capabilities have enabled our rapid growth in the pharmaceutical industry," says Satish Reddy, managing director and chief operating officer of the company. He adds, "The new facility is benchmarked to the highest global regulatory standards and is designed to cater to a global market that requires the most stringent standards of quality. We strongly believe that this unit will be one of the drivers of quantum growth for Dr Reddy's,"
The plant has a production capacity of manufacturing 40 million cytotoxic OSD capsules, 40 million anti-hormonal formulations and seven million injectibles per annum. The plant has an in-built capacity-expansion capability.
The unit has been designed to handle potent compounds using isolation technology, with equipment like a fully automated injectible filling line, single pot processors and wash-in-place tablet presses.
The new facility represents a significant advance in technical sophistication over the company's other FTO facilities, of which three are located in Hyderabad, one in Yanam near Kakinada and one in Baddi, Himachal Pradesh.
Its manufacturing facilities have been inspected by some of the world's most stringent regulatory authorities, including USFDA, MHA, MCC, and ANVISA, the company said in a filing with the BSE.